Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Response in Psychosis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current DSM-IV-defined diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS as assessed using the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-I/P) (First et al, 1998)~* Is in the first episode of illness. First episode is defined as having had 6 months or less of lifetime treatment with an antipsychotic.~* Has not responded sufficiently to treatment with an antipsychotic. Lack of response is defined as a rating at study entry of 4 (moderate) or more on at least one of the following BPRS-A items: conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content.~* Continuous antipsychotic treatment at the time of study entry of a minimum of 12 weeks with the same antipsychotic agent.~* Antipsychotic dosing at some point during the 12 weeks must have reached a sufficient dose for antipsychotic response (e.g. patients who received only low dose quetiapine for insomnia or anxiety would not qualify). Sufficient dose for second generation antipsychotics is defined as a minimum dose of risperidone 3 mg/day, olanzapine 10 mg/day, quetiapine 500 mg/day, ziprasidone 100 mg/day or aripiprazole 15 mg/day. Sufficient dose for first generation antipsychotics is defined as 3 mg/day of haloperidol or its equivalent for other first generation agents.~* Aged 15 to 40.~* If age 18 or older, competent and willing to sign informed consent.~* If under age 18, parent or guardian consent and subject assent.~* For women, a negative urine pregnancy test and agreement to use a medically accepted method of birth control.~Exclusion criteria:~* Meets DSM-IV criteria for a current substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, brief psychotic disorder, shared psychotic disorder, or a mood disorder (major depression or bipolar) with psychotic features.~* Persistence of psychotic symptoms due to nonadherence to antipsychotic medication.~* Medical contraindications to treatment with long-acting injectable risperidone.~* Serious neurological or endocrine disorder or medical condition /treatment known to affect the brain.~* A medical condition requiring medication with psychotropic effects.~* Clinical assessment that trial participation is contraindicated due to risk for homicidal or suicidal behavior.~* A diagnosis of diabetes (fasting glucose \> 126 mg/dl).~* Requires with antidepressant or mood stabilizing medication.~* Previous treatment with a long acting formulation of an antipsychotic

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- long-acting injectable risperidone (Type: EXPERIMENTAL): One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).